PCOLCE

Across TCGA pan-cancer cohorts, PCOLCE mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PCOLCE data layer compared with 22 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PCOLCE mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCOLCE expression acts as an unfavorable survival marker.

CCRCC, LSCC, and LUAD are the cancer types where PCOLCE mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.139	0.979	.001	36	view →
LSCC	OS	Quartile	All	0.712	0.928	.013	14	view →
LUAD	OS	Tertile	III,IV	0.553	0.848	.024	12	view →
PDAC	DFS	Median	IV	0.245	0.766	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PCOLCE–CCRCC (DFS)

Open the CCRCC breakdown →